ORGANIZATION

• NPhA Instructing Member Pharmacies on Careful Drug Purchases after Fake Harvoni Issue: Chief
  January 20, 2017

• JGA Head Frets Majority of Products Subject to Gap-Year Revisions Will Be Generics
  January 20, 2017

• We Must Redouble Efforts for Proper Drug Distribution, Pharmacist Group Says on Fake Harvoni Issue
  January 19, 2017

• OTC Industry Group Keen on Expanding Self-Medication Tax Break: Chief
  January 18, 2017

• JPMA Eager for Its Active Involvement in Drug Pricing Debates: Chief
  January 18, 2017

• JMA’s Nakagawa Pushes Price Cuts Even on Non-100 Billion Yen Products, Eyes Other Hep C Drugs
  January 18, 2017

• JGA Corrects Generic Share Data for Past 3 Years; July-Sept. Share at 65.1%
  January 16, 2017

• With Annual Revisions, Drug Wholesalers Will Be Negotiating Delivery Prices All Year: JPWA Chief
  January 12, 2017

• Tokyo Pharma Chief Naito Prods Govt to Secure Predictability of Pricing System
  January 10, 2017

• Building Personal Relationships Will Be Crucial: FPMAJ Director General
  January 6, 2017

• Annual Price Revisions Must Not Adversely Affect Distribution Environment: JPWA
  December 26, 2016

• Novo’s Ole Moelskov Bech to Helm EFPIA Japan from January
  December 26, 2016

• FPMAJ Accepts PMDA’s Fee Raise Plan, but Wants Tradeoff
  December 16, 2016

• JMA Wants Adjustment Rate as High as 5%: Yokokura
  December 15, 2016

• Daratumumab Affects Transfusion Tests, Scientific Societies Warn
  December 13, 2016

• Ongoing Discussions without Chuikyo Deplorable: JPWA Head
  December 12, 2016

• Annual Price Revisions Will Demotivate Pharmas, Foreign HQs Harboring Serious Concerns: PhRMA Japan Chief
  December 9, 2016

• Drug Pricing Policy Can’t Be Defined in 2-3 Weeks: PhRMA Exec
  December 6, 2016

• JPWA Shows Firm Opposition to Annual Revisions
  December 5, 2016

• Annual Price Revisions of All Drugs Unacceptable: JMA Chief
  December 1, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 43
• 44
• 45
• 46
• 47
• 48
• 49
• 50
• 51
• …
• Next ›
• 最終 »